NEW ORLEANS, March 1 Patients with hereditary angioedema (HAE) experience prodromal or early warning symptoms before nearly three-quarters of their HAE attacks, according to survey findings presented today at the 2010 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. According to researchers, this high frequency suggests that prodromal symptoms may reliably indicate when to initiate treatment to help prevent an acute HAE attack.
Advertisement
To identify the prodromal symptoms patients experienced before an HAE attack, two separate surveys were conducted. A prospective survey, administered to patients enrolled in an open-label study of human pasteurized C1 esterase inhibitor concentrate, surveyed patients about their prodromal symptoms at the time they were seeking treatment for an HAE attack. A retrospective survey focused on questions related to prodromal symptoms prior to the patient's last HAE attack.
Advertisement
According to survey findings, patients experienced prodromal symptoms before 70.5 percent of the 305 reported HAE attacks. The most commonly reported prodromal symptoms were fatigue (45%), gastrointestinal complaints (41%), muscle aches or flu-like symptoms (26%), rash (21%) and numbness or tingling (10%).
"To date there has been limited published data regarding the importance of identifying prodromal symptoms of an HAE attack," said Timothy J. Craig, D.O., Professor of Medicine and Pediatrics at Penn State University in Hershey, PA., and one of the study's investigators. "Our findings suggest that the onset of these warning signs may be the time to initiate on-demand treatment in order to prevent an acute attack of HAE."
HAE is a genetic disorder affecting approximately 6,000 to 10,000 Americans and is caused by a deficiency of C1-INH, which is inherited in an autosomal dominant manner. Patients who have abdominal attacks can experience episodes of severe pain, diarrhea, nausea, and vomiting caused by swelling of the intestinal wall. Attacks that involve the face and larynx can result in airway closure, asphyxiation, and, if untreated, death. Diagnosis of HAE requires a blood test to confirm low or abnormal levels of C1-INH.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufacturers and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.
Contact: Sheila A. Burke, Director, Communications & Public Relations Worldwide Commercial Operations CSL Behring C: 484-919-2618 O: 610-878-4209 [email protected]
SOURCE CSL Behring
